Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2016-05-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.116.232066PMID 26907622
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III

  2016influential reference
• Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans

  2015cited by this paper
• Utility of Bilirubins and Bile Acids as Endogenous Biomarkers for the Inhibition of Hepatic Transporters

  2015cited by this paper
• Characterization of the Transmembrane Transport and Absolute Bioavailability of the HCV Protease Inhibitor Danoprevir

  2015cited by this paper
• Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions

  2015cited by this paper
• Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline

  2015cited by this paper
• Dehydroepiandrosterone sulfate, a useful endogenous probe for evaluation of drug-drug interaction on hepatic organic anion transporting polypeptide (OATP) in cynomolgus monkeys.

  2015cited by this paper
• Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide (OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in Cynomolgus Monkeys

  2015influential reference
• Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake

  2015cited by this paper
• Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.

  2014cited by this paper
• N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin–trimethoprim interaction

  2014cited by this paper
• Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers

  2014cited by this paper
• Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.

  2014influential reference
• Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics.

  2014cited by this paper
• 6β-Hydroxycortisol Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving a Multispecific Renal Organic Anion Transporter, OAT3/SLC22A8, in Healthy Subjects

  2014influential reference
• The SLCO (former SLC21) superfamily of transporters.

  2013cited by this paper
• Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake.

  2013cited by this paper
• Evaluation of Endogenous Metabolic Markers of Hepatic CYP3A Activity Using Metabolic Profiling and Midazolam Clearance

  2013cited by this paper
• Investigation of Endogenous Compounds for Assessing the Drug Interactions in the Urinary Excretion Involving Multidrug and Toxin Extrusion Proteins

  2013cited by this paper
• Substrate-Dependent Inhibition of Organic Anion Transporting Polypeptide 1B1: Comparative Analysis with Prototypical Probe Substrates Estradiol-17β-Glucuronide, Estrone-3-Sulfate, and Sulfobromophthalein

  2013cited by this paper
• Pitavastatin as an In Vivo Probe for Studying Hepatic Organic Anion Transporting Polypeptide-Mediated Drug–Drug Interactions in Cynomolgus Monkeys

  2013cited by this paper
• Structure-Based Identification of OATP1B1/3 Inhibitors

  2013cited by this paper
• Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.

  2013cited by this paper
• Cynomolgus Monkey as a Potential Model to Assess Drug Interactions Involving Hepatic Organic Anion Transporting Polypeptides: In Vitro, In Vivo, and In Vitro-to-In Vivo Extrapolation

  2013influential reference
• N‐Methylnicotinamide Is an Endogenous Probe for Evaluation of Drug–Drug Interactions Involving Multidrug and Toxin Extrusions (MATE1 and MATE2‐K)

  2012cited by this paper
• Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.

  2012cited by this paper
• Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

  2012cited by this paper
• Urinary Elimination of Coproporphyrins Is Dependent on ABCC2 Polymorphisms and Represents a Potential Biomarker of MRP2 Activity in Humans

  2011cited by this paper
• Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

  2011cited by this paper
• 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans.

  2011cited by this paper
• Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin

  2010cited by this paper
• Impact of OATP transporters on pharmacokinetics

  2009cited by this paper
• Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

  2009cited by this paper
• Interaction of porphyrins with human organic anion transporting polypeptide 1B1.

  2009cited by this paper
• The current state of serum biomarkers of hepatotoxicity.

  2008cited by this paper
• Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism

  2008cited by this paper
• Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β‐Hydroxycholesterol

  2008cited by this paper
• Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

  2007cited by this paper
• Myocardial Infarction

  2006influential reference
• Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

  2006cited by this paper
• Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

  2004influential reference
• Cyclosporine-induced pseudoporphyria.

  2003cited by this paper
• Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer.

  2003cited by this paper
• [Dubin-Johnson syndrome].

  2001cited by this paper
• Hepatic Disposition of Fexofenadine: Influence of the Transport Inhibitors Erythromycin and Dibromosulphothalein

  2000cited by this paper
• Plasma porphyrins in the porphyrias.

  1999cited by this paper
• [Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome].

  1999cited by this paper
• Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome.

  1999cited by this paper
• Guide for the Care and Use of Laboratory Animals

  1996cited by this paper
• Physiological Parameters in Laboratory Animals and Humans

  1993influential reference
• Determining zinc coproporphyrin in maternal plasma--a new method for diagnosing amniotic fluid embolism.

  1992cited by this paper
• Plasma porphyrins in chronic renal failure.

  1990cited by this paper
• Diagnostic and pathogenetic implications of urinary coproporphyrin excretion in the Dubin-Johnson syndrome.

  1990cited by this paper
• Rifampicin-induced porphyria cutanea tarda.

  1980cited by this paper
• Rifampicin-induced porphyria cutanea tarda

  1980cited by this paper
• Rotor's syndrome. A distinct inheritable pathophysiologic entity.

  1976cited by this paper
• Coproporphyrin I and 3 excretion in bile and urine.

  1972influential reference
• Abnormal excretion of the isomers of urinary coproporphyrin by patients with Dubin-Johnson syndrome in Israel.

  1971cited by this paper
• An analysis of the porphyrins of normal and cirrhotic human liver and normal bile.

  1969cited by this paper
• Urinary coproporphyrin isomer distribution in the Dubin-Johnson syndrome.

  1967influential reference
• Ether-soluble porphyrins in bile, meconium and urine: a new appraisal by microscale counter-current analysis.

  1966cited by this paper
• Separation of urinary coproporphyrin isomers 1 and 3 by thin-layer chromatography. Studies in healthy subjects and patients with myocardial infarction.

  1966cited by this paper
• Urinary Excretion of Porphyrin Precursors and Coproporphyrin in Healthy Females on Oral Contraceptives

  1966cited by this paper
• STUDIES OF COPROPORPHYRIN. VII. ADAPTATION OF THE ERIKSEN PAPER CHROMATOGRAPHIC METHOD TO THE QUANTITATIVE ANALYSIS OF THE ISOMERS IN NORMAL HUMAN URINE.

  1964cited by this paper
• STUDIES OF COPROPORPHYRIN. VIII. REINVESTIGATION OF THE ISOMER DISTRIBUTION IN JAUNDICE AND LIVER DISEASES.

  1964cited by this paper

• Progress of coproporphyrin as an endogenous biomarker for transporter-mediated drug-drug interactions

  2026cites this paper
• Evaluation of OATP1B inhibitory potential using an endogenous biomarker coproporphyrin-I in new drug applications: Case reports submitted by 2024.

  2025cites this paper
• Assessing hepatic impairment with biomarker-informed physiologically based pharmacokinetic modeling: Strengths and limitations of the endogenous biomarker Coproporphyrin I.

  2025cites this paper
• Quantitative analysis of coproporphyrin and its precursors as endogenous biomarkers for drug-drug interactions involving OATP1B1 and OATP1B3 in monkeys.

  2025cites this paper
• Hepatic uptake of estradiol-3-glucuronide and estradiol-3-sulfate-17β-glucuronide by human organic anion transporting polypeptides 1B1, 1B3, and 2B1.

  2025cites this paper
• Exploring the main source of coproporphyrins: Observations on transport in red blood cells.

  2025cites this paper
• Investigation of an OATP1B inhibitory effect by a cyclic peptide using the endogenous biomarker coproporphyrin-I in monkeys.

  2025cites this paper
• Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV

  2025cites this paper
• Understanding Coproporphyrins and their Disposition: Coproporphyrinuria is Common, of Diverse Cause, and Rarely Indicates Porphyria.

  2025cites this paper
• Recent advances in mass spectrometry-based bioanalytical methods for endogenous biomarkers analysis in transporter-mediated drug-drug interactions

  2025cites this paper
• Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV

  2025cites this paper
• Potential amelioration of liver function by low-dose tolvaptan in heart failure patients

  2025cites this paper
• Coproporphyrin I as an in vitro fluorescent probe to measure OATP1B1 transport activity.

  2025cites this paper
• Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease

  2024cites this paper
• Organic anion transporting polypeptides: Pharmacology, toxicology, structure, and transport mechanisms.

  2024cites this paper
• Ultra-Sensitive Quantification of Coproporphyrin-I and -III in Human Plasma Using Ultra-Performance Liquid Chromatography Coupled to Quadrupole Time-of-Flight Mass Spectrometry

  2024cites this paper
• Increased coproporphyrin serum levels in healthy volunteers treated with the cholesterol uptake inhibitor ezetimibe

  2024influential citation
• Plasma and urinary CP I and CP III concentrations in chimeric mice with human hepatocytes after rifampicin administration

  2024influential citation
• Characterization and Prediction of Organic Anion Transporting Polypeptide 1B Activity in Prostate Cancer Patients on Abiraterone Acetate Using Endogenous Biomarker Coproporphyrin I

  2024cites this paper
• Significant increases in detection capability for assessment of organic anion transporting polypeptide-mediated drug-drug interaction in cynomolgus monkeys by modifying pretreatment of Coproporphyrin I and III, and glycochenodeoxycholate-3-sulfate in plasma.

  2024cites this paper
• An Isolated Perfused Rat Liver Model: Simultaneous LC-MS Quantification of Pitavastatin, Coproporphyrin I, and Coproporphyrin III Levels in the Rat Liver and Bile

  2024cites this paper
• Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.

  2024cites this paper
• Roles of the ABCG2 Transporter in Protoporphyrin IX Distribution and Toxicity

  2024cites this paper
• Building a Predictive PBPK Model for Human OATP Substrates: a Strategic Framework for Early Evaluation of Clinical Pharmacokinetic Variations Using Pitavastatin as an Example

  2024cites this paper
• Assessing Pleiotropic Effects of a Mixed-Mode Perpetrator Drug, Rifampicin, by Multiple Endogenous Biomarkers in Dogs

  2023cites this paper
• Differential Preincubation Effects of Nicardipine on OATP1B1- and OATP1B3-Mediated Transport in the Presence and Absence of Protein: Implications in Assessing OATP1B1- and OATP1B3-Mediated Drug–Drug Interactions

  2023cites this paper
• Quantification of OATP1B1 endogenous metabolites coproporphyrin I and III in human urine

  2023cites this paper
• Utilization of OATP1B Biomarker Coproporphyrin‐I to Guide Drug–Drug Interaction Risk Assessment: Evaluation by the Pharmaceutical Industry

  2023cites this paper
• The influence of OATP2B1 and atorvastatin on coproporphyrin isomers in rats.

  2023cites this paper
• Various effects of repeated rifampin dosing on coproporphyrin levels in humans

  2023cites this paper
• Influence of Slco2b1‐knockout and SLCO2B1‐humanization on coproporphyrin I and III levels in rats

  2023influential citation
• The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition–Progress from 2016 to 2023

  2023cites this paper
• Quantitative Prediction of OATP-Mediated Disposition and Biliary Clearance Using Human Liver Chimeric Mice

  2023cites this paper
• Evaluation of the Selectivity of Several Organic Anion Transporting Polypeptide 1B Biomarkers Using Relative Activity Factor Method

  2023cites this paper
• Characterization of Elimination Pathways and the Feasibility of Endogenous Metabolites as Biomarkers of Organic Anion Transporter 1/3 Inhibition in Cynomolgus Monkeys

  2023cites this paper
• Characterization of Bile Acid Sulfate Conjugates as Substrates of Human Organic Anion Transporting Polypeptides.

  2023cites this paper
• Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein–Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In Vivo

  2023cites this paper
• Cluster Gauss‐Newton method analyses of PBPK model parameter combinations of coproporphyrin‐I based on OATP1B‐mediated rifampicin interaction studies

  2022cites this paper
• The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study

  2022cites this paper
• Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin‐I and blood concentration of cyclosporin A in real‐world patients

  2022influential citation
• Characterization of endogenous markers of hepatic function in patients receiving itraconazole treatment for prophylaxis of deep mycosis.

  2022cites this paper
• SLCO1B1 Pharmacogenetics in Pediatrics

  2022cites this paper
• Hepatic solute carrier transporters and drug therapy: Regulation of expression and impact of genetic variation.

  2022cites this paper
• Isotretinoin and its Metabolites Alter mRNA of Multiple Enzyme and Transporter Genes In Vitro, but Downregulation of Organic Anion Transporting Polypeptide Does Not Translate to the Clinic

  2022cites this paper
• Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B

  2021cites this paper
• Organic Anion–Transporting Polypeptide 1B1/1B3–Mediated Hepatic Uptake Determines the Pharmacokinetics of Large Lipophilic Acids: In Vitro–In Vivo Evaluation in Cynomolgus Monkey

  2021cites this paper
• Relationship of hemoglobin level and plasma coproporphyrin‐I concentrations as an endogenous probe for phenotyping OATP1B

  2021cites this paper
• Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated clearance

  2021cites this paper
• OATP2B1 - the underrated member of the Organic Anion Transporting Polypeptide Family of drug transporters?

  2021cites this paper
• Application of a PBPK model to elucidate the changes of systemic and liver exposures for rosuvastatin, carotegrast, and bromfenac followed by OATP inhibition in monkeys

  2021cites this paper
• Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation

  2021influential citation
• Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates

  2021cites this paper
• Cynomolgus Monkey as an Emerging Animal Model to Study Drug Transporters: In Vitro, In Vivo, In Vitro-to-In Vivo Translation

  2021cites this paper
• OATP1B1/1B3-mediated hepatic uptake determines the pharmacokinetics of large lipophilic acids: In vitro–in vivo evaluation in cynomolgus monkey

  2021cites this paper
• Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development.

  2020cites this paper
• Role of transporters in drug disposition and drug-drug interactions

  2020cites this paper
• PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Inter‐Individual Variability

  2020cites this paper
• Endogenous Coproporphyrin I and III Are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TR-) Rats.

  2020cites this paper
• Genetic polymorphisms of human hepatic OATPs: functional consequences and effect on drug pharmacokinetics

  2020influential citation
• Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs.

  2020cites this paper
• Substantially Increased Plasma Coproporphyrin‐I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population

  2020cites this paper
• Detection of Weak Organic Anion–Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans

  2020cites this paper
• Absence of OATP1B (Organic Anion–Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression

  2020cites this paper
• Towards human ex vivo organ perfusion models to elucidate drug pharmacokinetics in health and disease

  2020cites this paper
• Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition

  2020cites this paper
• Elucidation of OATP1B1 and 1B3 transporter function using transgenic rodent models and commonly known single nucleotide polymorphisms.

  2020cites this paper
• Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry.

  2020cites this paper
• Recent progress in in vivo phenotyping technologies for better prediction of transporter-mediated drug-drug interactions.

  2020cites this paper
• Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III

  2020cites this paper
• Absence of OATP1B Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression

  2020influential citation
• Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for OATP Inhibition

  2020cites this paper
• Detection of Weak Organic Anion – Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans s

  2020influential citation
• Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug–Drug Interaction and Associated Biomarker Levels in Healthy Volunteers

  2019cites this paper
• In Vitro and In Vivo Methods to Assess Pharmacokinetic Drug-Drug Interactions in Drug Discovery and Development.

  2019cites this paper
• Organic Anion-Transporting Polypeptide Genes Are Not Induced by the Pregnane X Receptor Activator Rifampin: Studies in Hepatocytes In Vitro and in Monkeys In Vivo

  2019cites this paper
• SLC Family Transporters.

  2019cites this paper
• ABC Family Transporters.

  2019cites this paper
• Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A

  2019cites this paper
• Effect of Rifampicin on the Plasma Concentrations of Bile Acid-O-Sulfates in Monkeys and Human Liver-Transplanted Chimeric Mice With or Without Bile Flow Diversion.

  2019cites this paper
• Recovery of OATP1B Activity after Living Kidney Transplantation in Patients with End-Stage Renal Disease

  2019cites this paper
• Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers.

  2019cites this paper
• In Vitro–In Vivo Extrapolation of OATP1B-Mediated Drug–Drug Interactions in Cynomolgus Monkey

  2018cites this paper
• Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

  2018cites this paper
• Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I

  2018cites this paper
• PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3

  2018cites this paper
• In Vitro Stimulation of Multidrug Resistance-Associated Protein 2 Function Is Not Reproduced In Vivo in Rats

  2018influential citation
• Title: Comprehensive evaluation of the utility of 20 endogenous molecules as biomarkers of OATP1B inhibition compared to rosuvastatin and coproporphyrin I

  2018cites this paper
• Novel LC-MS assays impacting CYP and transporter drug-drug interaction evaluations.

  2018cites this paper
• Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys

  2018cites this paper
• Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition

  2018cites this paper
• A pharmaceutical industry perspective on transporter and CYP-mediated drug-drug interactions: kidney transporter biomarkers.

  2018cites this paper
• Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B‐Mediated Drug–Drug Interactions Using Population Pharmacokinetic Modeling and Simulation

  2018cites this paper
• UHPLC-MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions.

  2018cites this paper
• A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers.

  2018cites this paper
• Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug–Drug Interactions

  2018cites this paper
• Biomarkers for In Vivo Assessment of Transporter Function

  2018influential citation
• Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.

  2018cites this paper
• Clinical Pharmacokinetics and Drug–Drug Interactions of Elbasvir/Grazoprevir

  2018cites this paper
• Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter–Enzyme Interplay

  2018cites this paper
• Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides

  2017influential citation